Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor.
The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
David
D
Sanford
The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Hagop
H
Kantarjian
The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Jeffrey
J
Skinner
The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Elias
E
Jabbour
The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA jcortes@mdanderson.org.
Jorge
J
Cortes
D000328:Adult; D000368:Aged; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D011724:Pyridazines / Q000008:administration & dosage* / Q000009:adverse effects
D007093:Imidazoles; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; C545373:ponatinib
chronic myeloid leukemia; phase II; ponatinib; resistant; tyrosine kinase inhibitor